TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an update.
Paradigm Biopharmaceuticals announced its participation in the 4th Annual Evans & Partners Small Cap Healthcare Conference, where the company’s Founder and Managing Director, Paul Rennie, will present on the burden of osteoarthritis and Paradigm’s efforts to address this through a global Phase 3 clinical trial of iPPS for knee osteoarthritis. This presentation underscores Paradigm’s commitment to addressing unmet medical needs and could enhance its positioning within the biopharmaceutical industry, potentially impacting stakeholders by advancing treatment options for osteoarthritis.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company dedicated to improving patient health and quality of life by discovering, developing, and delivering pharmaceutical therapies. The company is currently focused on developing injectable pentosan polysulfate sodium (iPPS) for treating diseases where inflammation plays a significant role, such as osteoarthritis.
Average Trading Volume: 834,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$113M
Learn more about PAR stock on TipRanks’ Stock Analysis page.